^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TCR modulator

    Related drugs:
    7d
    PNOC018: Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    H3.3K27M
    |
    cyclophosphamide • fludarabine IV • KIND T
    20d
    RPTR-1-201-101: An early phase trial of RPTR-1-201 in Advanced Solid Tumors (2025-524010-28-00)
    P1/2, N=52, Not yet recruiting, Repertoire Immune Medicines Inc.
    New P1/2 trial
    |
    Keytruda (pembrolizumab)
    21d
    TITAN: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. (clinicaltrials.gov)
    P1, N=72, Recruiting, AstraZeneca | N=32 --> 72
    Enrollment change
    27d
    Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, USWM, LLC (dba US WorldMeds) | Trial completion date: Jul 2025 --> Jul 2026
    Trial completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    29d
    Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=108, Recruiting, AstraZeneca | N=24 --> 108
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    1m
    Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd.
    New P1 trial
    1m
    An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia (clinicaltrials.gov)
    P1, N=7, Completed, China Immunotech (Beijing) Biotechnology Co., Ltd. | Recruiting --> Completed | Trial completion date: Dec 2026 --> Feb 2026
    Trial completion • Trial completion date
    1m
    A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    TK-6302-01: A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:01 and a tumour protein called PRAME. (2025-521603-46-00)
    P1, N=24, Not yet recruiting, T-Knife GmbH
    New P1 trial